Could a blood pressure cuff cut heart attacks and strokes?
NCT ID NCT07270887
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a simple, non-invasive procedure called remote ischemic conditioning (RIC) can protect major organs in people with very high-risk atherosclerotic cardiovascular disease (ASCVD). RIC involves inflating a blood pressure cuff on the arms for short periods to trigger the body's natural defenses. Researchers will follow 2,800 participants over time to see if regular RIC sessions reduce the chance of heart attacks, strokes, kidney problems, and death.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- remote ischemic conditioning (RIC) using a blood pressure cuff on the arms
- What this could lead to
- If it works, this could provide a simple, drug-free way to lower the risk of heart attacks, strokes, and kidney problems in people with advanced heart disease.
- What could go wrong
- This is a large but early-stage study, and the treatment is still experimental. It may not reduce events as hoped, and the cuff inflation could cause discomfort or bruising.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,800 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
very high-risk ASCVD populations
- Ages
-
40 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age over 40 years * Two or more prior major ASCVD events; OR one documented major ASCVD event with two or more of the following risk factors * signed informed consent Note: Definition of Major ASCVD Events: A. Acute coronary syndrome within the past year. B. History of myocardial infarction (not part of a new acute coronary syndrome episode). C. Ischemic stroke or history of ischemic stroke. D. Symptomatic peripheral artery disease, defined as intermittent claudication with an ankle-brachial index (ABI) \< 0.85, or prior limb revascularization or amputation. Risk factors: 1. Age ≥65 y 2. Heterozygous familial hypercholesterolemia 3. History of prior coronary artery bypass surgery or percutaneous coronary intervention outside of the major 4. ASCVD event(s) 5. Diabetes mellitus 6. Hypertension 7. CKD (eGFR 15-59 mL/min/1.73 m2) 8. Current smoking 9. Persistently elevated LDL-C (LDL-C ≥100 mg/dL \[≥2.6 mmol/L\]) despite maximally tolerated statin therapy and ezetimibe 10. History of congestive HF Exclusion Criteria: * Presence of severe neurological deficit (mRS score ≥ 3) * Uncontrolled severe hypertension (systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg despite medication) * Subclavian artery stenosis ≥ 50% or presence of subclavian steal syndrome * Severe hematological disorders or significant coagulation abnormalities * Contraindications to remote ischemic conditioning, such as severe soft tissue injury, fracture, or vascular injury in the upper limbs, or peripheral vascular disease in the distal upper limbs * Severe comorbid conditions with a life expectancy of less than 1 year * Participation in another clinical trial within the past 3 months or ongoing participation * Any other circumstances deemed by the investigator as unsuitable for participation in this clinical study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASCVD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Neurology, General Hospital of Northern Theater Command
RECRUITINGShenyang, 110016, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden heart risks in testicular cancer survivors: a closer look at chemotherapy's long shadow
- Phone coach after heart attack may slash cholesterol and save lives
- Pharmacist phone calls could boost lifesaving statin use in heart patients
- Text reminders may boost statin refills in heart patients
- AI face scan could replace your Doctor's checkup?
- Which diabetes drug best protects your heart? 60,000-person study aims to find out.